Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

dasatinib

Known as: BMS dasatinib, Dasatinib [Chemical/Ingredient], N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase… Expand
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • table 1
  • table 2
Review
2018
Review
2018
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, the incidence of which increases with age. Tyrosine kinase… Expand
  • table 1
  • table 3
Review
2018
Review
2018
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed… Expand
Highly Cited
2011
Highly Cited
2011
Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2007
Highly Cited
2007
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2006
Highly Cited
2006
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Highly Cited
2006
Highly Cited
2006
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4